contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


epistem-completes-board-line-up-and-launches-new-ngs-service

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

MANCHESTER, United Kingdom, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Epistem Limited, the Manchester based pre-clinical and clinical research services company announces the completion of its Board ...

MANCHESTER, United Kingdom, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Epistem Limited, the Manchester based pre-clinical and clinical research services company announces the completion of its Board appointments. Benjamin Reed joins as Commercial Director. Ben was previously Pharmacogenomics Business Development Director at Epistem and now re-joins the company to lead the commercial team after 18 months at Primer Design, Limited, UK. Ben and James Fullerton-Batten (previously Finance Director, Concept Life Sciences) join the founder Executive Board members Julie Tudor (Operations Director) and Catherine Booth (CEO). The team are completed by Nick Ash (Non-Executive Chairman, formerly CEO Source BioScience plc) and Matt Pomroy (Non-Executive investor representative from Foresight Group). Investment from the Foresight group in June 2018 enabled expansion of the research services, the first of which is launched in December 2018 – GCLP compliant Next Generation Sequencing (NGS) services. This compliments the established PCR and Array based platforms that provide biomarker, target discovery and personalised medicine information from very limited quantities of RNA and DNA (e.g from biopsies). Dr. Catherine Booth, CEO, Epistem, commented: “I am looking forward to working with James and excited to welcome Ben back to lead the business team. We will continue to deliver high quality data to our customers, from often the most difficult sample types, using the latest technology. Small samples from biopsies or blood can be very precious – our proprietary upfront processing techniques, NGS capability and extensive Bioinformatics experience allow us to extract maximal information from every sample and allow customers to make the most informed decisions possible.” Notes for editors About Epistem Ltd  Epistem is an established research service provider with headquarters in Manchester UK. Originally founded on ground-breaking research in epithelial stem cell biology, it has evolved into a dynamic and successful business providing research services for both pre-clinical and clinical development across several specialist therapeutic areas, including oncology, dermatology and gastro-intestinal (GI) diseases and toxicity. For 18 years Epistem has been providing a personalised service to customers worldwide, from virtual start-ups to established biotechnology companies, global pharmaceutical and personal care companies. Epistem is committed to providing reliable, innovative and transferable pre-clinical and clinical models and services to support decision making throughout the drug discovery and development pipeline. <a href="https://www.globenewswire.com/Tracker?data=LWLVU0xDfbzEeAL4x7p7obMtBUw4fvb4vsI-oongNYevyzHedOjISuI8FbAwojJwzz1to6cpOrqQHDs489I57g==">www.epistem.co.uk</a> <img src="https://www.globenewswire.com/newsroom/ti?nf=NzQzNzY2MyMyNjA5NDEwIzIxMjEyODI=" width="1" height="1"/>

Epistem completes board line up and launches new NGS service

Financial Key Ratios: EV/EBIT, EV/EBITA, EV/EBITDA, and EV/Sales

Faron Pharmaceuticals

Herantis Pharma

Mendus

Probabilities of success in drug development

Nordea Bank

Nordea shareholder? It’s easier than ever to attend the AGM with a new digital set-up

Return on capital (ROE, ROI, ROIC, RONIC)

Balance sheet, debt leverage and risks